$RIGL
RIGEL PHARMACEUTICALS INC

2021 Q1 Form 10-Q Financial Statement

#000155837021005903 Filed on May 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $81.02M $55.76M
YoY Change 45.3% 341.71%
Cost Of Revenue $316.0K $155.0K
YoY Change 103.87% 40.91%
Gross Profit $80.70M $12.53M
YoY Change 544.33% 57.61%
Gross Profit Margin 99.61% 22.46%
Selling, General & Admin $22.12M $18.43M
YoY Change 20.03% -7.62%
% of Gross Profit 27.41% 147.15%
Research & Development $16.83M $16.15M
YoY Change 4.19% 47.48%
% of Gross Profit 20.85% 128.93%
Depreciation & Amortization $239.0K $171.0K
YoY Change 39.77% 6.88%
% of Gross Profit 0.3% 1.37%
Operating Expenses $38.95M $34.58M
YoY Change 12.63% 11.94%
Operating Profit $41.76M $21.03M
YoY Change 98.58% -191.65%
Interest Expense $485.0K $142.0K
YoY Change 241.55% -81.79%
% of Operating Profit 1.16% 0.68%
Other Income/Expense, Net
YoY Change
Pretax Income $41.27M $21.24M
YoY Change 94.28% -220.7%
Income Tax $1.800M $0.00
% Of Pretax Income 4.36% 0.0%
Net Earnings $39.50M $21.24M
YoY Change 85.94% -220.7%
Net Earnings / Revenue 48.75% 38.1%
Basic Earnings Per Share $0.23 $0.13
Diluted Earnings Per Share $0.22 $0.13
COMMON SHARES
Basic Shares Outstanding 169.8M 168.5M
Diluted Shares Outstanding 176.1M 168.6M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.30M $95.90M
YoY Change -59.02% -25.02%
Cash & Equivalents $20.05M $45.23M
Short-Term Investments $19.30M $50.70M
Other Short-Term Assets $8.300M $9.100M
YoY Change -8.79% 93.62%
Inventory $6.947M $1.600M
Prepaid Expenses
Receivables $142.2M $9.700M
Other Receivables $0.00 $0.00
Total Short-Term Assets $196.8M $116.3M
YoY Change 69.18% -16.51%
LONG-TERM ASSETS
Property, Plant & Equipment $2.498M $26.40M
YoY Change -90.54% -19.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $818.0K $700.0K
YoY Change 16.86% 0.0%
Total Long-Term Assets $19.24M $27.10M
YoY Change -29.02% -19.1%
TOTAL ASSETS
Total Short-Term Assets $196.8M $116.3M
Total Long-Term Assets $19.24M $27.10M
Total Assets $216.0M $143.4M
YoY Change 50.62% -17.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.095M $2.200M
YoY Change 131.59% 83.33%
Accrued Expenses $32.00M $26.90M
YoY Change 18.96% 14.96%
Deferred Revenue $9.500M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $52.02M $31.20M
YoY Change 66.74% 19.54%
LONG-TERM LIABILITIES
Long-Term Debt $19.80M $9.800M
YoY Change 102.04%
Other Long-Term Liabilities $57.53M $23.90M
YoY Change 140.72% -53.41%
Total Long-Term Liabilities $57.53M $33.70M
YoY Change 70.72% -34.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $52.02M $31.20M
Total Long-Term Liabilities $57.53M $33.70M
Total Liabilities $109.6M $64.90M
YoY Change 68.81% -16.26%
SHAREHOLDERS EQUITY
Retained Earnings -$1.266B
YoY Change
Common Stock $1.345B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $78.30M $78.50M
YoY Change
Total Liabilities & Shareholders Equity $216.0M $143.4M
YoY Change 50.62% -17.01%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income $39.50M $21.24M
YoY Change 85.94% -220.7%
Depreciation, Depletion And Amortization $239.0K $171.0K
YoY Change 39.77% 6.88%
Cash From Operating Activities -$19.96M -$3.093M
YoY Change 545.17% 442.63%
INVESTING ACTIVITIES
Capital Expenditures $71.00K $607.0K
YoY Change -88.3% -259.74%
Acquisitions
YoY Change
Other Investing Activities $7.600M $25.07M
YoY Change -69.68% -3681.43%
Cash From Investing Activities $7.532M $24.46M
YoY Change -69.21% -2386.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.097M 1.336M
YoY Change 56.96% 6580.0%
NET CHANGE
Cash From Operating Activities -19.96M -3.093M
Cash From Investing Activities 7.532M 24.46M
Cash From Financing Activities 2.097M 1.336M
Net Change In Cash -10.33M 22.70M
YoY Change -145.48% -1501.48%
FREE CASH FLOW
Cash From Operating Activities -$19.96M -$3.093M
Capital Expenditures $71.00K $607.0K
Free Cash Flow -$20.03M -$3.700M
YoY Change 441.24% 1847.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q1 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
CY2020Q1 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
RIGEL PHARMACEUTICALS INC
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001034842
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
196758000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
88983000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2498000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2676000
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
0-29889
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3248524
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1180 Veterans Blvd.
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2021Q1 dei City Area Code
CityAreaCode
650
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
624-1100
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
RIGL
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
170164333
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20047000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30373000
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
19298000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
26954000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
142195000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15973000
CY2021Q1 us-gaap Inventory Net
InventoryNet
6947000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1638000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8271000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14045000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15919000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17895000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
818000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
824000
CY2021Q1 us-gaap Assets
Assets
215993000
CY2020Q4 us-gaap Assets
Assets
110378000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5095000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3707000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6595000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9592000
CY2021Q1 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
5368000
CY2020Q4 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
4889000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11075000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11014000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8917000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8621000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9500000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3018000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
176069000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168568000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
39500000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
21243000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
21027000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
358000
CY2021Q1 us-gaap Interest Expense
InterestExpense
485000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5472000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
52022000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40841000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8296000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10651000
CY2021Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
19844000
CY2020Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
19815000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
57533000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5045000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
170000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
169000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1344601000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1339833000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1266472000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1305972000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
78298000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
34026000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
215993000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
110378000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81018000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55761000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
316000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
155000
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
16826000
CY2020Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
16149000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22121000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18430000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
39263000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
34734000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
41755000
CY2020Q1 us-gaap Interest Expense
InterestExpense
142000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
41271000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
21243000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1771000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
39500000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
21243000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
169800000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
168469000
CY2021Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
55000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
39503000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
21298000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
34026000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
39500000
CY2021Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2097000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2672000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
78298000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
53815000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
21243000
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
55000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1336000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2050000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
78499000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
39500000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
21243000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2639000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2024000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
239000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
171000
CY2021Q1 rigl Noncash Interest Expense
NoncashInterestExpense
60000
CY2021Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-85000
CY2020Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
138000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
126222000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-451000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5272000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
242000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5774000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-338000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-6000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-35000
CY2021Q1 rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
1976000
CY2020Q1 rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
1934000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1394000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1945000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2997000
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3312000
CY2021Q1 rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
479000
CY2020Q1 rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
735000
CY2021Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
61000
CY2020Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
209000
CY2021Q1 rigl Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2059000
CY2020Q1 rigl Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1417000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6482000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-23081000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
57900000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-98000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19955000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3093000
CY2021Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4297000
CY2020Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
13352000
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
11900000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
38420000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
71000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
607000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7532000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24461000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2097000
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1336000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2097000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1336000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10326000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
22704000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30373000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22521000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20047000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45225000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
358000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
203000
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Nature of O</b><b style="font-size:10pt;font-weight:bold;">perations</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Our pioneering research focuses on signaling pathways that are critical to disease mechanisms. Our first product approved by the United States Food and Drug Administration (FDA) is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only approved oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Fostamatinib is currently being studied in a Phase 3 trial for the treatment of warm autoimmune hemolytic anemia (wAIHA); a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19, a National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)-sponsored Phase 2 trial for the treatment of hospitalized patients with COVID-19, in collaboration with Inova Health System; and a Phase 2 trial for the treatment of COVID-19 being conducted by Imperial College London. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our other clinical programs include our interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly). In addition, we have product candidates in clinical development with partners AstraZeneca AB (AZ), BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi). </p>
CY2021Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Basis of Presentation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2020 has been derived from audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because certain disclosures required by U.S. GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p>
CY2021Q1 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
105000
CY2020Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
171000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
39500000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
21243000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
169800000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
168469000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
169800000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
168469000
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
6269000
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
99000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
176069000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168568000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8185000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23206000
CY2021Q1 rigl Share Based Compensation Number Of Stock Option Plans
ShareBasedCompensationNumberOfStockOptionPlans
2
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2639000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2024000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
9702519
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81018000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55761000
CY2020Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
6065000
CY2021Q1 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
3299000
CY2021Q1 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
3958000
CY2021Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
5406000
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
3332000
CY2020Q1 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
2232000
CY2020Q1 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
2009000
CY2020Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
3555000
CY2021Q1 rigl Sales Discounts And Allowances
SalesDiscountsAndAllowances
3700000
CY2021Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
5400000
CY2020Q1 rigl Sales Discounts And Allowances
SalesDiscountsAndAllowances
2700000
CY2021Q1 rigl Collaborative Arrangement Upfront Fee Received
CollaborativeArrangementUpfrontFeeReceived
125000000.0
CY2021Q1 us-gaap Accretion Expense
AccretionExpense
60000
CY2021Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
843000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1189000
CY2021Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
962000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
449000
CY2021Q1 us-gaap Inventory Net
InventoryNet
6947000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1638000
CY2021Q1 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
4000000.0
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
39345000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
57327000
CY2021Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
5142000
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
39345000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
57327000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20047000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30373000
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
19298000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
26954000
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
26398000
CY2021Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
26397000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
35856000
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
35852000
CY2021Q1 rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P39D
CY2020 rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P78D
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
18
CY2021Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17900000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
17200000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
19300000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M29D
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
229000
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
251000
CY2021Q1 us-gaap Lease Cost
LeaseCost
1569000
CY2020Q1 us-gaap Lease Cost
LeaseCost
1591000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1340000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1340000
CY2021Q1 rigl Lessee Leasing Arrangements Operating Leases Number Of Renewal Term Periods
LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTermPeriods
2
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
57000
CY2017Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
9328
CY2021Q1 rigl Expected Income From Sublease
ExpectedIncomeFromSublease
8500000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15900000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2496000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2400000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1667000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6667000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6667000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4999000
CY2021Q1 rigl Fixed Sublease Expense
FixedSubleaseExpense
1095000
CY2020Q1 rigl Fixed Sublease Expense
FixedSubleaseExpense
1095000
CY2021Q1 rigl Variable Sublease Expense
VariableSubleaseExpense
241000
CY2020Q1 rigl Variable Sublease Expense
VariableSubleaseExpense
223000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
1336000
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
1318000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7586000
CY2021Q1 rigl Sublease Payments To Be Received Next Twelve Months
SubleasePaymentsToBeReceivedNextTwelveMonths
3412000
CY2021Q1 rigl Lessee Operating Lease Liability Net Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityNetPaymentsRemainderOfFiscalYear
4174000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10485000
CY2021Q1 rigl Sublease Payments To Be Received Two Years
SubleasePaymentsToBeReceivedTwoYears
4716000
CY2021Q1 rigl Lessee Operating Lease Liability Net Payments Next Twelve Months
LesseeOperatingLeaseLiabilityNetPaymentsNextTwelveMonths
5769000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
877000
CY2021Q1 rigl Sublease Payments To Be Received Three Years
SubleasePaymentsToBeReceivedThreeYears
394000
CY2021Q1 rigl Lessee Operating Lease Liability Net Payments Due Year Two
LesseeOperatingLeaseLiabilityNetPaymentsDueYearTwo
483000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18948000
CY2021Q1 rigl Sublease Payments To Be Received
SubleasePaymentsToBeReceived
8522000
CY2021Q1 rigl Lessee Operating Lease Liability Net Payments
LesseeOperatingLeaseLiabilityNetPayments
10426000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
185000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
20000000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1800000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001558370-21-005903-index-headers.html Edgar Link pending
0001558370-21-005903-index.html Edgar Link pending
0001558370-21-005903.txt Edgar Link pending
0001558370-21-005903-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rigl-20210331.xsd Edgar Link pending
rigl-20210331x10q.htm Edgar Link pending
rigl-20210331x10q004.jpg Edgar Link pending
rigl-20210331x10q_htm.xml Edgar Link completed
rigl-20210331xex10d1.htm Edgar Link pending
rigl-20210331xex10d2.htm Edgar Link pending
rigl-20210331xex31d1.htm Edgar Link pending
rigl-20210331xex31d2.htm Edgar Link pending
rigl-20210331xex32d1.htm Edgar Link pending
rigl-20210331_cal.xml Edgar Link unprocessable
rigl-20210331_def.xml Edgar Link unprocessable
rigl-20210331_lab.xml Edgar Link unprocessable
rigl-20210331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending